Jentashapir Journal of Health Research

Published by: Kowsar

Investigation of Equivocal Expression of HER2 Gene by Immunohistochemistry in Patients with Invasive Breast Ductal Cancer Confirmed by CISH or FISH and Its Relationship with Clinicopathologic Variables

Fariba Binesh 1 , Amirmasoud Homayon 2 , Hassanali Vahedian Ardekani 3 , Sedighe Vaziribozorg 4 and Seyed Hossein Shahcheraghi 5 , 6 , *
Authors Information
1 Department of Pathology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2 Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3 Department of Oncology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
4 Department of Otolaryngology-Head and Neck Surgery, Otorhinolaryngology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
5 Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
6 Infectious Diseases Research Center, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Article information
  • Jentashapir Journal of Health Research: 9 (6); e89002
  • Published Online: July 13, 2019
  • Article Type: Research Article
  • Received: January 10, 2019
  • Accepted: June 23, 2019
  • DOI: 10.5812/jjhr.89002

To Cite: Binesh F , Homayon A , Vahedian Ardekani H , Vaziribozorg S , Shahcheraghi S H. Investigation of Equivocal Expression of HER2 Gene by Immunohistochemistry in Patients with Invasive Breast Ductal Cancer Confirmed by CISH or FISH and Its Relationship with Clinicopathologic Variables, Jentashapir J Health Res. Online ahead of Print ; 9(6):e89002. doi: 10.5812/jjhr.89002.

Copyright © 2019, Jentashapir Journal of Health Research. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. De Felice F, Musio D, Bulzonetti N, Raffetto N, Tombolini V. Relationship of clinical and pathologic nodal staging in locally advanced breast cancer: current controversies in daily practice? J Clin Med Res. 2014;6(6):409-13. doi: 10.14740/jocmr1908w. [PubMed: 25247013]. [PubMed Central: PMC4169081].
  • 2. Sinczak-Kuta A, Tomaszewska R, Rudnicka-Sosin L, Okon K, Stachura J. Evaluation of HER2/neu gene amplification in patients with invasive breast carcinoma. Comparison of in situ hybridization methods. Pol J Pathol. 2007;58(1):41-50. [PubMed: 17585541].
  • 3. Ivkovic-Kapicl T, Knezevic-Usaj S, Djilas-Ivanovic D, Panjkovic M. Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer. In Vivo. 2007;21(4):673-8. [PubMed: 17708365].
  • 4. Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications. Mol Biol Int. 2014;2014:852748. doi: 10.1155/2014/852748. [PubMed: 25276427]. [PubMed Central: PMC4170925].
  • 5. Mostafa NA, Eissa SS, Belal DM, Shoman SH. Assessment of Her-2/neu gene amplification status in breast carcinoma with equivocal 2+ Her-2/neu immunostaining. J Egypt Natl Canc Inst. 2011;23(1):41-6. doi: 10.1016/j.jnci.2011.07.006. [PubMed: 22099935].
  • 6. Hanna WM, Ruschoff J, Bilous M, Coudry RA, Dowsett M, Osamura RY, et al. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol. 2014;27(1):4-18. doi: 10.1038/modpathol.2013.103. [PubMed: 23807776].
  • 7. Panjwani P, Epari S, Karpate A, Shirsat H, Rajsekharan P, Basak R, et al. Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization and immunohistochemistry: Experience of a tertiary cancer referral centre in India. Indian J Med Res. 2010;132:287-94. [PubMed: 20847375].
  • 8. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48-72. doi: 10.1043/1543-2165-134.7.e48. [PubMed: 20586616].
  • 9. Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol. 2004;22(5):854-63. doi: 10.1200/JCO.2004.04.158. [PubMed: 14990641].
  • 10. Dowsett M, Bartlett J, Ellis IO, Salter J, Hills M, Mallon E, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol. 2003;199(4):418-23. doi: 10.1002/path.1313. [PubMed: 12635131].
  • 11. Musa ZA, Qasim BJ, Al Shaikhly AWAK. Evaluation of immunohistochemistry-equivocal (2+) HER2 gene status in invasive breast cancer by silver DNA in situ hybridization (SISH) and its association with clinicopathological variables. Iran J Pathol. 2017;12(1):9-19. [PubMed: 29760748]. [PubMed Central: PMC5938719].
  • 12. Meijer SL, Wesseling J, Smit VT, Nederlof PM, Hooijer GK, Ruijter H, et al. HER2 gene amplification in patients with breast cancer with equivocal IHC results. J Clin Pathol. 2011;64(12):1069-72. doi: 10.1136/jclinpath-2011-200019. [PubMed: 21836036].
  • 13. Mehrazma M, Kalantari E, Rezvani H, Bahar B, Basi A, Razavi SM, et al. Chromogenic in situ hybridisation test for breast cancer patients with equivocal IHC results--a study from Iran. Asian Pac J Cancer Prev. 2015;16(17):7695-700. doi: 10.7314/apjcp.2015.16.17.7695. [PubMed: 26625783].
  • 14. Zhang H, Ren G, Wang X, Zhao J, Yao H, Bai Y, et al. HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases. Breast Cancer Res Treat. 2012;134(2):743-9. doi: 10.1007/s10549-012-2101-x. [PubMed: 22678158].
  • 15. Lewis JT, Ketterling RP, Halling KC, Reynolds C, Jenkins RB, Visscher DW. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am J Clin Pathol. 2005;124(2):273-81. doi: 10.1309/J9VX-ABUG-KC4Y-07DL. [PubMed: 16040300].
  • 16. Crowe JP, Patrick RJ, Rybicki LA, Escobar PF, Weng D, Thomas Budd G, et al. A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution. Breast. 2006;15(6):728-35. doi: 10.1016/j.breast.2006.03.005. [PubMed: 16716590].
  • 17. Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner T, et al. Do we need HER-2/neu testing for all patients with primary breast carcinoma? Cancer. 2003;98(12):2547-53. doi: 10.1002/cncr.11828. [PubMed: 14669272].
  • 18. Rosenberg CL. Polysomy 17 and HER-2 amplification: True, true, and unrelated. J Clin Oncol. 2008;26(30):4856-8. doi: 10.1200/JCO.2008.17.2684. [PubMed: 18794542].
  • 19. Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B, et al. Her-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol. 2001;19(2):354-63. doi: 10.1200/JCO.2001.19.2.354. [PubMed: 11208826].
  • 20. Ehinger A, Malmstrom P, Bendahl PO, Elston CW, Falck AK, Forsare C, et al. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. Acta Oncol. 2017;56(1):68-74. doi: 10.1080/0284186X.2016.1237778. [PubMed: 27762648].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments